Pulmonary eosinophilia may indicate onset stage of allergic bronchopulmonary aspergillosis.
Aspergillus
Eosinophilia
Eosinophilic pneumonia
Ground-glass opacities
Immunoglobulin E
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
18 Nov 2021
18 Nov 2021
Historique:
received:
20
07
2021
accepted:
06
11
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
20
11
2021
Statut:
epublish
Résumé
Allergic bronchopulmonary aspergillosis (ABPA) and chronic eosinophilic pneumonia (CEP) both display peripheral eosinophilia as well as pulmonary infiltration, together described as pulmonary eosinophilia, and differentiation is sometimes problematic. This study therefore examined the distinctions between ABPA with and without CEP-like shadows. This retrospective cohort study from a single center included 25 outpatients (median age, 65 years) with ABPA diagnosed between April 2015 and March 2019, using criteria proposed by the International Society of Human and Animal Mycology (ISHAM), which focuses on positive specific IgE for Aspergillus fumigatus. Patients were assigned to either the eosinophilic pneumonia (EP) group or Non-EP group, defined according to findings on high-resolution computed tomography (HRCT). The EP group included patients with HRCT findings compatible with CEP; i.e., the presence of peripheral consolidation (p-consolidation) or ground-glass opacities (GGO), with no evidence of high-attenuation mucus. The Non-EP group comprised the remaining patients, who showed classical findings of ABPA such as mucoid impaction. Differences between the groups were analyzed. Baseline characteristics, frequency of a history of CEP (EP, 50% vs. Non-EP, 26%) and tentative diagnosis of CEP before diagnosis of ABPA (67% vs. 16%) did not differ significantly between groups. Although elevated absolute eosinophil count and Aspergillus-specific immunoglobulin E titers did not differ significantly between groups, the Non-EP group showed a strong positive correlation between these values (R = 0.7878, p = 0.0003). The Non-EP group displayed significantly higher levels of the fungal marker beta-D glucan (median, 11.7 pg/ml; interquartile range, 6.7-18.4 pg/ml) than the EP group (median, 6.6 pg/ml; interquartile range, 5.2-9.3 pg/ml). Both groups exhibited frequent recurrence of shadows on X-rays but no cases in the EP group had progressed to the Non-EP group at the time of relapse. The ABPA subgroup with imaging findings resembling CEP experienced frequent recurrences, as in typical ABPA. In pulmonary eosinophilia, even if there are no shadows indicating apparent mucous change, the Aspergillus-specific immunoglobulin E level is important in obtaining an accurate diagnosis and in the selection of appropriate therapies for this type of ABPA.
Sections du résumé
BACKGROUND
BACKGROUND
Allergic bronchopulmonary aspergillosis (ABPA) and chronic eosinophilic pneumonia (CEP) both display peripheral eosinophilia as well as pulmonary infiltration, together described as pulmonary eosinophilia, and differentiation is sometimes problematic. This study therefore examined the distinctions between ABPA with and without CEP-like shadows.
METHODS
METHODS
This retrospective cohort study from a single center included 25 outpatients (median age, 65 years) with ABPA diagnosed between April 2015 and March 2019, using criteria proposed by the International Society of Human and Animal Mycology (ISHAM), which focuses on positive specific IgE for Aspergillus fumigatus. Patients were assigned to either the eosinophilic pneumonia (EP) group or Non-EP group, defined according to findings on high-resolution computed tomography (HRCT). The EP group included patients with HRCT findings compatible with CEP; i.e., the presence of peripheral consolidation (p-consolidation) or ground-glass opacities (GGO), with no evidence of high-attenuation mucus. The Non-EP group comprised the remaining patients, who showed classical findings of ABPA such as mucoid impaction. Differences between the groups were analyzed.
RESULTS
RESULTS
Baseline characteristics, frequency of a history of CEP (EP, 50% vs. Non-EP, 26%) and tentative diagnosis of CEP before diagnosis of ABPA (67% vs. 16%) did not differ significantly between groups. Although elevated absolute eosinophil count and Aspergillus-specific immunoglobulin E titers did not differ significantly between groups, the Non-EP group showed a strong positive correlation between these values (R = 0.7878, p = 0.0003). The Non-EP group displayed significantly higher levels of the fungal marker beta-D glucan (median, 11.7 pg/ml; interquartile range, 6.7-18.4 pg/ml) than the EP group (median, 6.6 pg/ml; interquartile range, 5.2-9.3 pg/ml). Both groups exhibited frequent recurrence of shadows on X-rays but no cases in the EP group had progressed to the Non-EP group at the time of relapse.
CONCLUSIONS
CONCLUSIONS
The ABPA subgroup with imaging findings resembling CEP experienced frequent recurrences, as in typical ABPA. In pulmonary eosinophilia, even if there are no shadows indicating apparent mucous change, the Aspergillus-specific immunoglobulin E level is important in obtaining an accurate diagnosis and in the selection of appropriate therapies for this type of ABPA.
Identifiants
pubmed: 34794492
doi: 10.1186/s13223-021-00624-4
pii: 10.1186/s13223-021-00624-4
pmc: PMC8600892
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118Informations de copyright
© 2021. The Author(s).
Références
Chest. 2009 Mar;135(3):805-826
pubmed: 19265090
Eur Respir J. 2018 Sep 18;52(3):
pubmed: 30049743
Curr Probl Diagn Radiol. 2016 May-Jun;45(3):168-73
pubmed: 26323654
Ann Allergy. 1993 Apr;70(4):333-8
pubmed: 8466099
Clin Chest Med. 2016 Sep;37(3):535-56
pubmed: 27514599
Thorax. 1981 May;36(5):345-9
pubmed: 7314002
PLoS One. 2013 Apr 12;8(4):e61105
pubmed: 23593402
Chest. 2007 Oct;132(4):1183-90
pubmed: 17646221
J Allergy Clin Immunol. 2015 Aug;136(2):312-22.e7
pubmed: 25746970
Br J Radiol. 1989 Jan;62(733):1-5
pubmed: 2914186
Allergol Int. 2014 Mar;63(1):133-5
pubmed: 24368582
PLoS One. 2010 Dec 15;5(12):e15346
pubmed: 21179536
Allergol Int. 2019 Jul;68(3):370-371
pubmed: 30670338
Chest. 2018 Mar;153(3):656-664
pubmed: 29331473
Can Assoc Radiol J. 1996 Oct;47(5):374-7
pubmed: 8857974
Allergol Int. 2019 Oct;68(4):413-419
pubmed: 31253537
J Allergy Clin Immunol. 2021 Apr;147(4):1261-1268.e5
pubmed: 32920094
Thorax. 1989 Nov;44(11):919-24
pubmed: 2595632
Clin Exp Allergy. 2013 Aug;43(8):850-73
pubmed: 23889240
Ann Intern Med. 1977 Apr;86(4):405-14
pubmed: 848802
Arch Intern Med. 1986 May;146(5):916-8
pubmed: 3516103
Allergol Int. 2018 Jan;67(1):79-84
pubmed: 28546015
J Allergy Clin Immunol. 2016 Mar;137(3):690-7
pubmed: 26947981
Respir Med. 2012 Jul;106(7):942-7
pubmed: 22445696